Gradian Diagnostics
Gradian Diagnostics is a privately held, Miami Beach-based biotechnology company founded in 2018 that claims to develop next-generation medical and diagnostics technologies. Its public footprint is limited to a single 2019 funding round of ~$3.1M, and its corporate website is currently offline.
- Company typePrivate
- Founded2018
- HeadquartersMiami Beach, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Gradian Diagnostics firmographics
Firmographics- Name
- Gradian Diagnostics
- Website
- https://gradian-dx.com
- Company type
- Private
- Founded year
- 2018
- Headcount range
- 11–50 employees
- Short description
- Gradian Diagnostics is a privately held, Miami Beach-based biotechnology company founded in 2018 that claims to develop next-generation medical and diagnostics technologies. Its public footprint is limited to a single 2019 funding round of ~$3.1M, and its corporate website is currently offline.
- Ownership category
- akta.pro rank
Where Gradian Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Miami Beach
- HQ country
- United States
- HQ region
- North America
Markets served
Gradian Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Gradian Diagnostics product offering
Product offeringCore offering
Gradian Diagnostics is a biotechnology company that develops next-generation medical and diagnostics technologies. The company focuses on creating advanced diagnostic products and platforms intended for use by healthcare providers and clinical laboratories. Specific product lines, assay menus, or instrument details are not disclosed in available source material.
Differentiator
Problem solved
Functional benefit
Companies that use Gradian Diagnostics
Customer profileIdeal customer profiles1 record
Gradian Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Gradian Diagnostics competitors and assessment
Company assessmentBroad incumbents
- Hologic: Diversified diagnostics and women's health company with major molecular diagnostics products (e.g., Panther); broadly incumbent in the same diagnostics category Gradian targets.
- QIAGEN: Global provider of molecular diagnostics sample technologies and assays, with a broad diagnostics portfolio relevant to any next-gen diagnostics developer.
- Abbott Diagnostics: One of the largest diagnostics incumbents globally, with molecular, immunoassay, and point-of-care platforms; a broad comparable for a smaller next-gen diagnostics challenger.
Emerging players
- Accelerate Diagnostics: Smaller public diagnostics company focused on rapid antimicrobial resistance identification; comparable as an emerging next-gen diagnostics peer with similar capital-intensity profile.
- T2 Biosystems: Diagnostics company developing direct-from-sample molecular detection products; comparable as a small-cap next-gen diagnostics peer navigating similar commercialization challenges.
Direct peers
- Cepheid (Danaher): Developer of the GeneXpert molecular diagnostics platform widely used for rapid infectious-disease testing; directly comparable as a next-generation diagnostics technology provider serving clinical and hospital customers.
- QuidelOrtho: Diagnostics company focused on immunoassays and rapid testing across clinical settings; comparable as a peer in next-generation medical diagnostics commercialization.
- GenMark Diagnostics: Molecular diagnostics company (acquired by Roche) whose ePlex platform automated syndromic testing; a directly comparable next-gen diagnostics business that was a strategic acquisition target.
- BioFire Diagnostics (bioMérieux): Syndromic molecular diagnostics developer (FilmArray) with a similar next-gen testing platform business model targeting hospitals and reference labs.
Regional players
- Mesa Labs: Diagnostics and measurement-focused life sciences tools company; comparable as a smaller peer in the medical/clinical diagnostics and measurement space.
Market position
Customer concentration
Gradian Diagnostics social profiles
Digital presenceGradian Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gradian Diagnostics leadership team
Management profileNumber of profiles
Profiles1 record
Gradian Diagnostics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gradian Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gradian Diagnostics
What does Gradian Diagnostics do?
Gradian Diagnostics is a biotechnology company that develops next-generation medical and diagnostics technologies. The company focuses on creating advanced diagnostic products and platforms intended for use by healthcare providers and clinical laboratories. Specific product lines, assay menus, or instrument details are not disclosed in available source material.
When was Gradian Diagnostics founded?
Gradian Diagnostics was founded in 2018. It employs 11 to 50 people.
Where is Gradian Diagnostics based?
Gradian Diagnostics is headquartered in Miami Beach, United States, in the North America region.
Who are Gradian Diagnostics's main competitors?
Broad incumbents on record are Hologic, QIAGEN and Abbott Diagnostics. Emerging players are Accelerate Diagnostics and T2 Biosystems. Direct peers are Cepheid (Danaher), QuidelOrtho, GenMark Diagnostics and BioFire Diagnostics (bioMérieux). Mesa Labs is listed as a regional player.
Does Gradian Diagnostics have an API?
No public API is recorded for Gradian Diagnostics.